| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S12727 R48004 |
Bjørk (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
1.27 [1.07;1.50] excluded (control group) |
133/7,950 68,295/4,463,879 | 68,428 | 7,950 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12728 R48007 |
Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 0.81 [0.67;0.99] C | 133/7,950 443/21,634 | 576 | 7,950 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8978 R30439 |
Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 | Diagnosis Disorders of psychological development (F80–F89) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.50 [1.00;2.10] | 27/2,813 9,949/1,707,707 | 9,976 | 2,813 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8937 R30212 |
Charlton (Lamotrigine) (Controls unexposed, disease free), 2017 | Neurodevelopmental disorders (at 6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No Matched |
0.42 [0.03;6.86] C excluded (control group) |
0/122 58/6,048 | 58 | 122 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8938 R30213 |
Charlton (Lamotrigine) (Controls unexposed, sick), 2017 | Neurodevelopmental disorders (at 6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 0.20 [0.01;3.47] C | 0/122 9/472 | 9 | 122 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8933 R30193 |
Bromley (Lamotrigine) (Controls unexposed, disease free), 2013 | Neurodevelopmental disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: Yes |
4.06 [0.55;22.20] excluded (control group) |
2/30 4/214 | 6 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8936 R30209 |
Bromley (Lamotrigine) (Controls unexposed, sick), 2013 | Neurodevelopmental disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 4.64 [0.21;101.27] C | 2/30 0/26 | 2 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8952 R30277 |
Rihtman (Lamotrigine), 2013 | Children: special education (Preschool children: mean age 4-5y) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 1.24 [0.08;20.50] C | 1/42 1/52 | 2 | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8919 R30142 |
Dean (Lamotrigine), 2007 | Neurodevelopmental disorder (mean age in years: m1=1.5 and m0=15.25) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 1.73 [0.07;40.78] C | 0/4 3/46 | 3 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.08 [0.66;1.76] | 10,568 | 10,961 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Lamotrigine) (Controls unexposed, sick) (Mixed indications; 2: Lamotrigine) (Controls unexposed NOS) (Mixed indications; 3: Lamotrigine) (Controls unexposed, sick; 4: Lamotrigine) (Controls unexposed, sick; 5: Lamotrigine; 6: Lamotrigine;
Asymetry test p-value = 0.5896 (by Egger's regression)
slope=-0.1376 (0.1780); intercept=0.4854 (0.8288); t=0.5856; p=0.5896
excluded 8933, 8937, 12727